Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

294.55
+4.201.45%
Post-market: 294.550.00000.00%19:56 EDT
Volume:893.53K
Turnover:264.76M
Market Cap:34.89B
PE:-79.54
High:300.00
Open:297.50
Low:293.51
Close:290.35
Loading ...

Company Profile

Company Name:
BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
11000
Office Location:
Aeschengraben 27,21st Floor,Basel,Basel-Stadt,Switzerland
Zip Code:
4051
Fax:
- -
Introduction:
BeOne Medicines Ltd., formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Directors

Name
Position
John V. Oyler
Co-Founder, Chairman and Chief Executive Officer
Ranjeev Krishana
Lead Director
Alessandro Riva
Director
Anthony C. Hooper
Director
Corazon D. Sanders
Director
Margaret Dugan
Director
Michael Goller
Director
Olivier Brandicourt
Director
Qingqing Yi
Director
Shalini Sharp
Director
Xiaodong Wang
Director

Shareholders

Name
Position
John V. Oyler
Co-Founder, Chairman and Chief Executive Officer
Xiaobin Wu
President, Chief Operating Officer and General Manager, China
Aaron Rosenberg
Chief Financial Officer
Chan Lee
Senior Vice President, General Counsel
Lai Wang
Global Head of R&D
Titus Ball
Chief Accounting Officer